X0306 4 2022-02-28 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001722360 Stark David Matthew C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 Exec. VP Chief Legal Officer Ordinary Shares 2022-02-28 4 M 0 18430 A 27832.39 D Ordinary Shares 2022-02-28 4 S 0 6452 8.1422 D 21380.39 D Restricted Share Units 2022-02-28 4 M 0 18430 0.00 D Ordinary Shares 18430 36860 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on February 28, 2020, with 18,430 having vested on each of February 28, 2021 and February 28, 2022, and 18,430 vesting on each of February 28, 2023 and February 28, 2024. /s/ Dov Bergwerk as attorney-in-fact for David M. Stark 2022-03-02